ZA200608361B - Crystalline polymorph of bazedoxifene acetate - Google Patents
Crystalline polymorph of bazedoxifene acetateInfo
- Publication number
- ZA200608361B ZA200608361B ZA200608361A ZA200608361A ZA200608361B ZA 200608361 B ZA200608361 B ZA 200608361B ZA 200608361 A ZA200608361 A ZA 200608361A ZA 200608361 A ZA200608361 A ZA 200608361A ZA 200608361 B ZA200608361 B ZA 200608361B
- Authority
- ZA
- South Africa
- Prior art keywords
- crystalline polymorph
- bazedoxifene acetate
- bazedoxifene
- acetate
- polymorph
- Prior art date
Links
- OMZAMQFQZMUNTP-UHFFFAOYSA-N acetic acid;1-[[4-[2-(azepan-1-yl)ethoxy]phenyl]methyl]-2-(4-hydroxyphenyl)-3-methylindol-5-ol Chemical compound CC(O)=O.C=1C=C(OCCN2CCCCCC2)C=CC=1CN1C2=CC=C(O)C=C2C(C)=C1C1=CC=C(O)C=C1 OMZAMQFQZMUNTP-UHFFFAOYSA-N 0.000 title 1
- 229960003713 bazedoxifene acetate Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Indole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US56058404P | 2004-04-07 | 2004-04-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200608361B true ZA200608361B (en) | 2010-03-31 |
Family
ID=34965585
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200608361A ZA200608361B (en) | 2004-04-07 | 2006-10-06 | Crystalline polymorph of bazedoxifene acetate |
Country Status (20)
Country | Link |
---|---|
US (1) | US7683052B2 (uk) |
EP (1) | EP1732889A1 (uk) |
JP (2) | JP2007532548A (uk) |
KR (1) | KR20070004815A (uk) |
CN (1) | CN1938271A (uk) |
AR (1) | AR048683A1 (uk) |
AU (1) | AU2005233114A1 (uk) |
BR (1) | BRPI0509257A (uk) |
CA (1) | CA2561296A1 (uk) |
EC (1) | ECSP066910A (uk) |
GT (1) | GT200500080A (uk) |
IL (1) | IL178101A0 (uk) |
NO (1) | NO20065046L (uk) |
PA (1) | PA8629201A1 (uk) |
PE (1) | PE20060173A1 (uk) |
RU (1) | RU2006132352A (uk) |
TW (1) | TW200536845A (uk) |
UA (1) | UA86055C2 (uk) |
WO (1) | WO2005100314A1 (uk) |
ZA (1) | ZA200608361B (uk) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0612586A2 (pt) * | 2005-06-29 | 2010-11-23 | Wyeth Corp | formulações de estrogênios conjugados e bazedoxifeno |
CN101304731B (zh) * | 2005-08-24 | 2012-06-20 | 惠氏公司 | 醋酸苯卓昔芬制剂及其生产方法 |
PE20090100A1 (es) * | 2007-03-30 | 2009-02-26 | Wyeth Corp | Metodos de separacion y deteccion de acetato de bacedoxifeno en composiciones farmaceuticas |
CZ302358B6 (cs) * | 2007-07-25 | 2011-03-30 | Zentiva, A. S. | Nové soli bazedoxifenu |
US20100016290A1 (en) * | 2008-02-11 | 2010-01-21 | Livius Cotarca | Amorphous polymorph of bazedoxifene acetate |
RU2010133603A (ru) * | 2008-02-11 | 2012-03-20 | ВАЙЕТ ЭлЭлСи (US) | Способ получения полиморфной формы а базедоксифена ацетата |
ITMI20091109A1 (it) * | 2009-06-23 | 2010-12-24 | Wyeth Corp | Forma polimorfa d di bazedoxifene acetato e metodi per la sua preparazione |
ES2436841T3 (es) | 2009-10-27 | 2014-01-07 | Wyeth Llc | Formulaciones de bazedoxifeno con antioxidantes |
WO2012007453A1 (en) | 2010-07-14 | 2012-01-19 | Sandoz Ag | Crystalline compound of 1-[4-(2-azepan-1-ylethoxy)benzyl]-2-(4-hydroxyphenyl)-3-methyl-1h-indol-5-ol |
EP2407467A1 (de) | 2010-07-14 | 2012-01-18 | Sandoz Ag | Kristalline Verbindung von 1-[4-(2-azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol und Milchsäure |
US9212172B2 (en) | 2010-09-14 | 2015-12-15 | Dr. Reddy's Laboratories Limited | Preparation of crystalline bazedoxifene and its salts |
EP2471770A1 (en) | 2010-12-28 | 2012-07-04 | Sandoz Ag | Method of preparing polymorphic pure form A of bazedoxifene acetate |
CN103864664A (zh) * | 2012-12-18 | 2014-06-18 | 江苏柯菲平医药有限公司 | 巴多昔芬乙酸盐新晶型及其制备方法 |
WO2014186325A1 (en) | 2013-05-15 | 2014-11-20 | Indiana University Research And Technology Corporation | Processes and intermediates for preparing indole pharmaceuticals |
CN103864665B (zh) * | 2014-03-04 | 2016-03-02 | 苏州特瑞药业有限公司 | 醋酸巴多昔芬的制备方法 |
CN104030963A (zh) * | 2014-06-30 | 2014-09-10 | 四川大学 | 一种巴多昔芬醋酸盐晶型a的制备方法 |
CN111004165A (zh) * | 2019-12-03 | 2020-04-14 | 南京正济医药研究有限公司 | 一种醋酸巴多昔芬晶型a的制备方法 |
US11246874B1 (en) | 2021-04-20 | 2022-02-15 | Oxygen Biotech LLC | Treatment of COVID-19 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW397821B (en) | 1996-04-19 | 2000-07-11 | American Home Produits Corp | 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof |
US5780497A (en) * | 1996-04-19 | 1998-07-14 | American Home Products Corporation | 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents |
ATE206701T1 (de) | 1996-04-19 | 2001-10-15 | American Home Prod | Östrogene verbindungen |
US5998402A (en) * | 1996-04-19 | 1999-12-07 | American Home Products Corporation | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents |
US5880137A (en) * | 1996-04-19 | 1999-03-09 | American Home Products Corporation | 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents |
ID24417A (id) * | 1997-10-15 | 2000-07-20 | American Home Prod | Ariloksi-alkil-dialkilamina yang baru |
US6005102A (en) * | 1997-10-15 | 1999-12-21 | American Home Products Corporation | Aryloxy-alkyl-dialkylamines |
US6479535B1 (en) * | 1998-05-15 | 2002-11-12 | Wyeth | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations |
AR029538A1 (es) * | 2000-07-06 | 2003-07-02 | Wyeth Corp | Composiciones farmaceuticas de agentes estrogenicos |
EP1336602A1 (en) | 2002-02-13 | 2003-08-20 | Giovanni Scaramuzzino | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases |
CA2489813A1 (en) * | 2002-06-25 | 2003-12-31 | Wyeth | Use of thio-oxindole derivatives in treatment of hormone-related conditions |
JP2007532560A (ja) * | 2004-04-07 | 2007-11-15 | ワイス | バゼドキシフェンアセテートの結晶多形 |
-
2005
- 2005-04-06 TW TW094110849A patent/TW200536845A/zh unknown
- 2005-04-06 EP EP05735042A patent/EP1732889A1/en not_active Withdrawn
- 2005-04-06 WO PCT/US2005/011423 patent/WO2005100314A1/en active Application Filing
- 2005-04-06 RU RU2006132352/04A patent/RU2006132352A/ru not_active Application Discontinuation
- 2005-04-06 AU AU2005233114A patent/AU2005233114A1/en not_active Withdrawn
- 2005-04-06 PA PA20058629201A patent/PA8629201A1/es unknown
- 2005-04-06 UA UAA200610608A patent/UA86055C2/uk unknown
- 2005-04-06 AR ARP050101366A patent/AR048683A1/es unknown
- 2005-04-06 CN CNA2005800103454A patent/CN1938271A/zh not_active Withdrawn
- 2005-04-06 JP JP2007507417A patent/JP2007532548A/ja not_active Abandoned
- 2005-04-06 GT GT200500080A patent/GT200500080A/es unknown
- 2005-04-06 BR BRPI0509257-4A patent/BRPI0509257A/pt not_active IP Right Cessation
- 2005-04-06 KR KR1020067020645A patent/KR20070004815A/ko not_active Application Discontinuation
- 2005-04-06 PE PE2005000385A patent/PE20060173A1/es not_active Application Discontinuation
- 2005-04-06 CA CA002561296A patent/CA2561296A1/en not_active Abandoned
- 2005-04-06 US US11/100,998 patent/US7683052B2/en active Active
-
2006
- 2006-09-14 IL IL178101A patent/IL178101A0/en unknown
- 2006-10-06 EC EC2006006910A patent/ECSP066910A/es unknown
- 2006-10-06 ZA ZA200608361A patent/ZA200608361B/xx unknown
- 2006-11-02 NO NO20065046A patent/NO20065046L/no not_active Application Discontinuation
-
2008
- 2008-06-30 JP JP2008171116A patent/JP2009007361A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
AU2005233114A1 (en) | 2005-10-27 |
IL178101A0 (en) | 2006-12-31 |
WO2005100314A1 (en) | 2005-10-27 |
PA8629201A1 (es) | 2005-11-25 |
EP1732889A1 (en) | 2006-12-20 |
GT200500080A (es) | 2005-10-31 |
CN1938271A (zh) | 2007-03-28 |
UA86055C2 (uk) | 2009-03-25 |
TW200536845A (en) | 2005-11-16 |
CA2561296A1 (en) | 2005-10-27 |
RU2006132352A (ru) | 2008-05-20 |
ECSP066910A (es) | 2006-12-20 |
US20050250762A1 (en) | 2005-11-10 |
JP2007532548A (ja) | 2007-11-15 |
US7683052B2 (en) | 2010-03-23 |
AR048683A1 (es) | 2006-05-17 |
PE20060173A1 (es) | 2006-04-12 |
KR20070004815A (ko) | 2007-01-09 |
BRPI0509257A (pt) | 2007-09-11 |
NO20065046L (no) | 2006-11-06 |
JP2009007361A (ja) | 2009-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI346105B (en) | Crystalline polymorph of bazedoxifene acetate | |
ZA200608361B (en) | Crystalline polymorph of bazedoxifene acetate | |
SI1802579T1 (sl) | Derivati 3-arilaminopiridina | |
IL180358A0 (en) | Crystalline form iv of linezolid | |
IL233392A0 (en) | Bazedoxifene Acetate composition | |
IL196706A0 (en) | Crystalline forms of rapamycin analogs | |
ZA200903971B (en) | Crystalline modification of fipronil | |
EP1804582A4 (en) | POLYMORPH SHAPES OF TADALAFIL | |
ZA200903967B (en) | Crystalline modification of fipronil | |
ZA200903970B (en) | Crystalline modification of fipronil | |
IL183380A0 (en) | Crystalline forms of linezolid intermediate | |
ZA200903972B (en) | Crystalline modification of fipronil | |
IL193399A0 (en) | Novel crystalline forms of armodafinil and preparation thereof | |
GB0509720D0 (en) | Configuration of VPNs | |
IL181597A0 (en) | Process for isolation of crystalline tacrolimus | |
HK1099755A1 (en) | Crystalline pyrazole derivative | |
EP1858844A4 (en) | NEW CRYSTALLINE FORMS OF ANTIDIABETIC COMPOUNDS | |
EP2170329A4 (en) | 7-ETHYL-10-HYDROXYCAMPTOTHECIN CRYSTALLINE POLYMORPH | |
SI1812422T1 (sl) | Kristalna oblika irbesartana | |
IL195061A0 (en) | Crystalline forms of atorvastatin | |
EP1878719A4 (en) | HYDROXYNOREPHEDRINE DERIVATIVE HYDROCHLORIDE POLYMORPH CRYSTAL | |
IL195092A0 (en) | Crystalline form of (s)-1-phenylethylammonium (r)-diphenyl-methanesulphinyl-acetate | |
IL191546A0 (en) | Process for the preparation of purified crystalline cci-779 | |
SI1814858T1 (sl) | Nove kristalne oblike nelfinavir mesilata | |
IL187326A0 (en) | Crystalline form of benzazepinium maleate derivative |